17 October 2023 | Tuesday | News
Image Source : Public Domain
Phase 2 is a randomized, double-blind, dose comparison study to evaluate the efficacy, safety and pharmacokinetics of CAN103 in newly treated GD patients, with extension period. This trial will serve as a potential registrational trial for CAN103.
CAN103 is the first clinical stage enzyme replacement therapy (ERT) being developed for GD in China. According to Frost & Sullivan, there were approximately 3,000 GD patients in China in 2020. Due to reimbursement barriers, most patients with GD in China currently lack access to approved ERT treatments. CAN103 is an ERT under development by CANbridge, as part of its rare disease collaboration with WuXi Biologics (2269.HK), for the long-term treatment of adults and children with GD Types I and III.